重组人PDCD1(PD-1)(CD279)

特别提示：包括重组人PDCD1(PD-1)(CD279)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人PDCD1(PD-1)(CD279)
英文名称：Recombinant Human Programmed Cell Death Protein 1

产品货号：重组人PDCD1(PD-1)(CD279)
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Leu25-Gln167在C端带有Fc标签。

PDCD1/PD-1/CD279质量控制：＞95%(还原性SDS-PAGE)

PDCD1/PD-1/CD279制剂：冻干品

PDCD1/PD-1/CD279保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

PDCD1/PD-1/CD279复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于PDCD1/PD-1/CD279：
Programmed cell death protein 1(PDCD1) is a single-pass type I membrane protein and contains 1 Ig-like V-type domain. PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PDCD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. PDCD1 has been suggested to be involved in lymphocyte clonal selection and peripheral tolerance, and thus contributes to the prevention of autoimmune diseases. As a cell surface molecule, PDCD1 regulates the adaptive immune response. Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function.

除了重组人PDCD1(PD-1)(CD279),，我公司还供应以下相关产品：



名称：重组小鼠TL1A(TNFSF15)
货号：JN0497
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备而成，目的基因编码的Ile76-Leu252表达纯化得来。

TL1A/TNFSF15质量控制：＞95%(还原性SDS-PAGE)

TL1A/TNFSF15制剂：冻干品

TL1A/TNFSF15保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

TL1A/TNFSF15复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于TL1A/TNFSF15：
Tumor Necrosis Factor Ligand Superfamily Member 15 (TNFSF15) is a new member of the tumor necrosis factor family. TNFSF15 is predominantly an endothelial cell-specific gene, and recombinant TNFSF15 is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. TNFSF15 exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli and programmed cell death of proliferating cells. These activities are highly specific to endothelial cells. TNFSF15 is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that TNFSF15 functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.